在瘤学中准衰老:癌症的新兴治疗途径
Satoru Meguro1, Syunta Makabe1, Kei Yaginuma1
1Department of Urology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Current oncology (Toronto, Ont.)
|August 27, 2025
概括
细胞衰老与衰老相关的过程在癌症中起着双重作用. 针对老化细胞使用老化疗法, 特别是结合老化诱导疗法, 显示未来癌症治疗的希望.
科学领域:
- 癌症学
- 细胞生物学
- 老年学
背景情况:
- 细胞衰老与衰老和癌症发展密切相关.
- 衰老可以通过阻止瘤增殖来抑制瘤,也可以通过分泌因子和改变细胞表面来促进癌症.
- 瘤微环境中的衰老细胞,包括纤维细胞,内皮细胞和免疫细胞,可以推动癌症的进展.
研究的目的:
- 探索细胞衰老在癌症中的多方面的作用.
- 审查治疗诱导的衰老对癌症结果的影响.
- 讨论老年治疗药物作为一种新的癌症治疗策略的潜力.
主要方法:
- 对癌症细胞衰老研究的文献综述.
- 对衰老在瘤抑制和促进中的双重作用的分析.
- 检查老化疗法及其与诱导老化的疗法的组合.
主要成果:
- 衰老表现出矛盾的效果,抑制增殖,同时可能通过对膜信号和表面蛋白质变化促进瘤生长.
- 治疗诱导的衰老会影响癌症治疗的有效性和结果.
- 老年疗法正在成为有前途的治疗途径, 目前正在进行临床试验.
结论:
- 细胞衰老是癌症生物学中的一个关键因素,
- 老化疗法,特别是与老化诱导策略相结合时,代表了癌症的治疗方法的发展.
- 需要进一步的研究来优化老年治疗在临床瘤学中的应用.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Replicative Cell Senescence
3.7K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.7K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


